INCIVO® (Telaprevir) Approved in Europe Offering Higher Cure Rates for Genotype-1 Chronic Hepatitis C Compared to Standa

Tibotec Virco-Virology BVBA, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, is a global pharmaceutical and research development company. The Company's main research and development facilities are in Beerse, Belgium with offices in Titusville, NJ and Cork, Ireland. Tibotec is dedicated to the discovery and development of innovative HIV/AIDS and hepatitis C drugs, and anti-infectives for diseases of high unmet medical need.

About Janssen

The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology , immunology, neuroscience, infectious disease, and cardiovascular and metabolic diseases.

Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world.

More information can be found at http://www.janssen-emea.com

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.

These statements are based on current expectations of future events.

If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Tibotec Virco-Virology BVBA, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; trends toward health care cost containment; and increased scrutiny of the healthcare industry by government agencies.

A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2011.

Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson.

The Janssen Pharmaceutical Companies and Johnson & Johnson do not undertake to update any forward-looking statements as a result of new information or future events or developments.

References:

        
        1) John McHutchinson et al. Telaprevir in Combination with
          Peginterferon and Ribavirin in Genotype 1 HCV Treatment-Naïve Patients:
          Final Results of Phase 3 ADVANCE study. Paper presented at: The Liver
          Meeting of the American Association for the Study of Liver Diseases
          (AASLD); 2010.
        2) Zeuzem S, Andreone P, Pol S et al. REALIZE trial final results:
          telaprevir-based regimen for genotype 1 hepatitis C virus infection in
          patients with prior null response, partial response or relapse to
          peginterferon/ribavirin. Paper presented at: 46th annual meeting of the
          European Association for the Study of the Liver (EASL); 2011.
        3) Sherman, K et al. Telaprevir incombination with pegiterferon
          alfa2a and ribavirin for 24 or 48 weeks in treatment-naïve genotype-1
          HCV patients who achieved an extended rapid viral response: Final
          results of phase 3 ILLUMINATE study. Paper presented at: The Liver
          Meeting of the American Association for the Study of Liver Diseases
          (AASLD); 2010.
        4) INCIVO(R) Summary of Product Characteristics 2011.
        5) WHO. State of the art of vaccine research and development.
          Viral Cancers. Available from
          http://www.who.int/vaccine_research/docu...).
        6) World Health Organization. Hepatitis C. Weekly Epidemiological
          Record. 1997;72:65-69.
        7) Centres for Disease Control and Prevention. Hepatitis C FAQs.
          [cited 2009 Dec 17] Available from:
          http://www.cdc.gov/hepatitis/C/cFAQ.htm#....
        8) Simin M et al. Cochrane systematic review: peginterferon
          alfaplus ribavirin vs. interferon plus ribavirin for chronic hepatitis
          C. Alimentary Pharmacology & Therapeutics. 2007; 25(10):1153-62.
        9) Nikolai Mühlberger et al. HCV-related burden of disease in
          Europe: a systematic assessment of incidence, prevalence, morbidity, and
          mortality. BMC Public Health. 2009; 9(34):1-14.
          10) The Hepatitis C Trust. Treatments: Potential New Drugs. [cited
          2010 Feb 20] Available from:
          http://www.hepctrust.org.uk/treatment/potential-new-drugs/Dr...
          .

    Video:
    http://multivu.prnewswire.com/mnr/prne/j...

CONTACT: MEDIA CONTACT: Daniel De Schryver, +49-173-7689-149; INVESTORRELATIONS: Stan Panasewicz, +1-732-524-2524, Louise Mehrotra,+1-732-524-6491